Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma Inc has demonstrated a strong financial position, ending the latest quarter with cash, cash equivalents, and marketable securities totaling $320 million, a $23 million increase from the previous quarter, driven primarily by a successful private placement. The company's advance in clinical data, particularly the positive outcomes associated with product candidates like LYL273 in third-line colorectal cancer (CRC), suggests a solidification of its competitive position within the CAR-T market. Enhanced expert feedback and rising probability of approval for its treatments underscore the company’s potential for success in capturing a larger market share, particularly in solid tumors beyond its current focus.

Bears say

The financial analysis of Lyell Immunopharma Inc. highlights several fundamental concerns that contribute to a negative outlook on the company's stock. A notable decrease in R&D spending from $34.9 million to $28.2 million between the second and third quarters of 2025 raises questions about the company's commitment to advancing its clinical pipeline. Additionally, critical risks remain unaddressed, including challenges in capturing market share in the CAR-T market, potential declines in treatment efficacy, emerging safety concerns, and the possibility of long-term shareholder dilution, all of which may hinder the company's prospects in a competitive market environment.

Lyell Immunopharma (LYEL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.